Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Automated Breast Ultrasound Systems Market Size & Share 2026-2035
Report ID: GMI728
|
Published Date: October 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Automated Breast Ultrasound Systems Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Automated Breast Ultrasound Systems Market Size
The automated breast ultrasound systems market was valued at USD 2.45 billion in 2025, is projected to reach USD 2.84 billion in 2026, and is expected to grow at a 16.0% CAGR (2026-2035) to attain USD 10.81 billion by 2035. The market includes dedicated automated breast ultrasound systems (ABUS), automated breast volume scanners (ABVS), and general-purpose ultrasound systems configured for breast imaging, measured through demand-side procurement revenue across hospitals, diagnostic imaging centers, and ambulatory care settings.
Automated Breast Ultrasound Systems Market Key Takeaways
Market Leader: GE Healthcare led with over 23.1% market share in 2025.
Leading Players: Top 5 players in this market include GE Healthcare, Siemens Healthineers, Philips, Samsung Medison, Mindray, which collectively held a market share of 74.1% in 2025.
The automated breast ultrasound systems market is moving from operator-dependent handheld examinations toward standardized volumetric acquisition. This change is being reinforced by dense-breast supplemental-imaging needs, regulatory disclosure requirements, and platform advances that improve scan consistency and radiologist workflow. Procurement is consequently shifting from isolated equipment decisions toward broader screening-capacity planning.
GMI Analyst View
Our discussions with clinical procurement teams and imaging department administrators across key markets indicate that the automated breast ultrasound systems market generated revenues of USD 2.25 billion in 2024, reflecting measured pre-regulatory adoption before the sharper demand acceleration anticipated through the forecast horizon.
Automated Breast Ultrasound Systems Market Trends, Growth Drivers & GMI Forecast Outlook
Demand is being shaped by the interaction of clinical need, screening-policy implementation, and workflow economics. Disease burden and dense-breast notification requirements expand the rationale for supplemental imaging, while acquisition cost, incomplete screening infrastructure, and reader-training constraints determine how quickly that rationale converts into installed systems.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Breast cancer is the most commonly diagnosed cancer among women worldwide and the second most common cancer overall, creating a durable clinical basis for greater screening and diagnostic imaging capacity [1]Bray F, et al. "Global Cancer Statistics 2024: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 34 Cancers in 186 Countries." pmc.ncbi.nlm.nih.gov. As organized screening broadens beyond mature markets, providers need modalities that can integrate into mammography-led pathways while addressing patients for whom mammographic sensitivity is limited. That requirement supports equipment demand across both screening networks and diagnostic referrals.
The MQSA notification requirement makes breast-density communication an operational responsibility for certified mammography facilities [2]U.S. Food & Drug Administration. "Important Information: Final Rule to Amend the Mammography Quality Standards Act (MQSA)." fda.gov. For providers, this changes supplemental imaging from a discretionary service-line consideration into a capability that must be evaluated within patient-navigation and referral workflows. ABUS is well aligned with mammography-centered settings because standardized acquisition can make supplemental examinations more scalable across multi-site networks.
AI-enabled acquisition and reading functions address a commercial constraint that is as important as clinical performance: the availability of specialist interpretation time. Systems that verify coverage, reduce scan variation, and prioritize suspicious findings can improve throughput without requiring the same expansion in expert-reader capacity. Studies cited by GE HealthCare reported a 35.7% increase in cancer detection when ABUS was combined with mammography versus mammography alone in dense-breast populations [4]GE HealthCare. "GE HealthCare to Feature Latest Advancements in Diagnostic Accuracy and Patient-Centered Breast Care at SBI 2025 Breast Cancer Imaging Symposium." businesswire.com. The resulting productivity case is strongest where screening volumes are high enough to justify dedicated workflows.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Dedicated ABUS acquisition competes with other capital priorities, including imaging upgrades, staffing, and facility expansion. Smaller hospitals and independent imaging centers frequently require clearer reimbursement visibility, service support, and predictable examination volumes before committing to a specialized platform. General-purpose ultrasound can remain an attractive alternative where a single system must support multiple clinical applications.
Low mammography participation constrains the near-term addressable base for a modality primarily used as an adjunct to breast screening. OECD evidence shows that screening participation remains below a quarter of the target-age population in several Asia Pacific markets [6]OECD. "Incidence, Screening and Mortality for Breast Cancer: Health at a Glance: Asia/Pacific 2024." oecd.org. Equipment demand can strengthen as governments and private providers add primary screening capacity, but supplemental-imaging investment generally follows rather than precedes that infrastructure build-out.
Volumetric ABUS interpretation also introduces a utilization risk. Facilities must develop competency in navigating coronal reconstructions, identifying acquisition artifacts, and integrating ABUS findings into established diagnostic pathways. Manufacturer training, teleradiology, and AI assistance can reduce this burden, but uneven reader capacity can delay the point at which an installed system delivers its intended clinical and economic value.
GMI Analyst View
We view the market as increasingly divided between institutions that can convert regulatory, workflow, and screening-volume advantages into dedicated-platform adoption and those that remain dependent on general-purpose ultrasound. The forecast therefore reflects durable demand expansion, but not a uniform migration across provider types or healthcare systems.
Automated Breast Ultrasound Systems Market Segment Analysis
By Product Type
The automated breast ultrasound systems market's ABUS segment held a 23.5% share in 2025 and is forecast to expand at a 20.0% CAGR (2026-2035). Purpose-built acquisition and standardized volumetric datasets make ABUS particularly relevant to high-throughput supplemental-screening settings, where reducing operator variation and improving reading consistency can justify specialized capital investment.
Other products, including conventional and general-purpose ultrasound systems configured for breast imaging, generated USD 1.80 billion in 2025 and are expected to account for a 63.4% share by 2035. Their continuing importance reflects a broad installed base and the purchasing logic of providers that require multi-application imaging capability, particularly where dedicated-platform utilization would not yet support a separate capital commitment.
GMI Analyst View
We expect product selection to remain a service-model decision rather than a simple technology substitution. Dedicated systems should gain where screening programs value standardization at scale, while versatile ultrasound platforms will remain commercially resilient where providers must balance breast imaging with broader diagnostic demand.
Automated Breast Ultrasound Systems Market Regional Analysis
North America Automated Breast Ultrasound Systems Market Analysis
The automated breast ultrasound systems market in North America is projected to reach USD 3.89 billion by 2035 and held a 43.0% global share in 2025. Mature breast-imaging infrastructure, reimbursement support, and the federal dense-breast notification framework create a particularly favorable setting for supplemental-imaging procurement [2]U.S. Food & Drug Administration. "Important Information: Final Rule to Amend the Mammography Quality Standards Act (MQSA)." fda.gov. Institutional demand is concentrated in provider networks that can link notification, referral, acquisition, and interpretation into a consistent care pathway.
US
The US generated USD 969 million in 2025 and is projected to reach USD 3.58 billion by 2035. Its scale reflects a dense network of mammography facilities, tertiary-care systems, and multi-site imaging groups. Compliance-related demand is broadening the commercial case for ABUS beyond early-adopter sites, while established procurement processes favor suppliers able to provide clinical training, service coverage, and integration support.
Canada
Canada is projected to generate USD 311 million by 2035 and accounted for 8.0% of the North American market in 2025. Provincial screening programs and academic health centers provide the principal adoption base, although health technology assessment, public-capital planning, and regional budget cycles can extend purchase timelines. These conditions favor measured deployment rather than rapid, fragmented installation.
Europe Automated Breast Ultrasound Systems Market Analysis
Europe generated USD 588 million in 2025 and is projected to account for a 20.0% share of global revenue by 2035. Organized screening programs and evidence-based procurement shape a market in which clinical validation, pathway fit, and replacement timing carry substantial weight. Publicly funded systems can support durable demand, though adoption typically progresses through structured evaluation rather than rapid equipment turnover.
Germany
Germany generated USD 112 million in 2025 and is projected to reach USD 411 million by 2035. The country's organized screening infrastructure, specialist capacity, and university-hospital ecosystem support the adoption of advanced ultrasound platforms. Demand is reinforced where imaging centers can incorporate standardized supplemental examinations into established diagnostic protocols.
UK
The UK is projected to reach USD 367 million by 2035 and held a 17.0% share of the European market in 2025. NHS breast-screening infrastructure provides an established route through which supplemental imaging capability can be assessed and deployed. Procurement remains tied to evidence, capacity priorities, and the practical fit of ABUS within hospital imaging workflows.
France
France accounted for a 15.0% share of the European market in 2025 and is projected to reach USD 324 million by 2035. Its combination of organized screening and a substantial ambulatory radiology base creates multiple adoption channels. Standardized automated acquisition can be attractive where hospital and independent-practice providers seek to improve consistency across distributed breast-imaging services.
Italy
Italy is projected to reach USD 261 million by 2035 and held a 12.1% share of the European market in 2025. Existing clinical familiarity with breast ultrasound provides a useful base for gradual automation, particularly in regions with active public screening initiatives and private diagnostic capacity. Adoption is likely to depend on local reimbursement clarity and provider willingness to redesign workflow around volumetric imaging.
Spain
Spain generated USD 53 million in 2025 and is projected to hold a 9.0% share of the European market by 2035. Regional screening programs and national-health-system modernization support a steady replacement and upgrade opportunity. Demand should remain selective, with purchase decisions shaped by hospital-network priorities and the ability to embed ABUS into established imaging pathways.
Asia Pacific Automated Breast Ultrasound Systems Market Analysis
The automated breast ultrasound systems market in Asia Pacific held a 23.0% global share in 2025 and is forecast to grow at a 20.2% CAGR (2026-2035). Expanding screening infrastructure, improving diagnostic capacity, and a clinically relevant dense-breast population create a substantial long-term opportunity. Studies cited by GE HealthCare indicate that 70% of Asian women have dense breast tissue [3]GE HealthCare. "GE HealthCare Launches AI-Driven, Patient-Friendly Invenia ABUS Premium to Accelerate Scanning and Drive Early Cancer Detection in Dense Breasts." investor.gehealthcare.com, which strengthens the clinical rationale for supplemental imaging as screening access develops.
China
China is projected to generate USD 1.07 billion by 2035 and accounted for 30.0% of the Asia Pacific market in 2025. The country's scale makes screening infrastructure expansion and remote-reading capability important determinants of demand. Providers can use automated acquisition to extend more consistent imaging protocols across geographically dispersed networks, though adoption will vary materially by city tier and care setting.
Japan
Japan generated USD 113 million in 2025 and is projected to reach USD 714 million by 2035. Established screening activity, a private examination culture, and sophisticated medical-device adoption create favorable conditions for supplemental-imaging technology. The market is particularly suited to platforms that fit well into quality-focused imaging workflows and advanced radiology practice.
India
India is projected to reach USD 535 million by 2035 and accounted for 14.9% of the Asia Pacific market in 2025. Demand is concentrated in corporate hospital systems and specialized oncology centers, where capital availability and patient awareness are more developed than in the broader public-health system. Wider adoption will depend on the pace at which primary screening, referral networks, and trained-reader capacity are expanded.
South Korea
South Korea generated USD 79 million in 2025 and is projected to reach USD 500 million by 2035. A developed private imaging sector and domestic manufacturing participation provide a supportive environment for advanced breast ultrasound. Competition is likely to center on clinical workflow, localization, and pricing, rather than on basic access to imaging technology.
Australia
Australia is projected to reach USD 285 million by 2035 and accounted for 8.0% of the Asia Pacific market in 2025. A mature public screening program and well-resourced radiology sector provide a stable foundation for adoption. The commercial opportunity is linked to incremental clinical acceptance of supplemental imaging and disciplined capital replacement among hospital and independent-provider groups.
Latin America Automated Breast Ultrasound Systems Market Analysis
Latin America generated USD 123 million in 2025 and is projected to reach USD 594 million by 2035. Demand is supported by cancer-detection investment and private-provider expansion, but procurement remains sensitive to macroeconomic conditions, import costs, and uneven imaging infrastructure. Brazil and Mexico anchor regional opportunity because they combine larger patient pools with comparatively developed hospital and diagnostic-center networks.
Brazil
Brazil generated USD 74 million in 2025 and is projected to reach USD 357 million by 2035. The country's public hospital network and active private healthcare sector create complementary routes to adoption. A well-established role for breast ultrasound in diagnostic practice supports progressive upgrading where reimbursement and provider economics support dedicated automation.
Mexico
Mexico is projected to generate USD 121 million by 2035 and accounted for 20.3% of the Latin American market in 2025. Large hospital chains, social-security institutions, and metropolitan imaging centers form the core procurement base. Premium-system adoption will remain moderated by purchasing-power constraints, while broader diagnostic-imaging access can expand the longer-term opportunity.
MEA Automated Breast Ultrasound Systems Market Analysis
MEA held a 5.0% global share in 2025 and is projected to generate USD 594 million by 2035. Gulf healthcare investment, cancer-awareness initiatives, and private-hospital expansion create the most immediate demand centers, while broader regional uptake remains dependent on budget availability and screening infrastructure. The market is consequently characterized by concentrated premium demand alongside more gradual public-sector diffusion.
Saudi Arabia
Saudi Arabia generated USD 31 million in 2025 and is projected to reach USD 150 million by 2035. Hospital modernization, women's-health initiatives, and government-backed healthcare investment provide a foundation for advanced diagnostic-imaging procurement. Adoption should be strongest among major medical centers and private networks with the clinical volume to support specialized breast-imaging workflows.
UAE
The UAE is projected to generate USD 121 million by 2035 and accounted for 20.3% of the MEA market in 2025. Private hospitals and specialized radiology centers drive demand for premium imaging technology, supported by high healthcare expenditure and a service-oriented provider environment. Continued capacity expansion can reinforce adoption, particularly where providers compete on differentiated diagnostic services.
South Africa
South Africa generated USD 18 million in 2025 and is projected to hold a 14.6% share of the MEA market by 2035. Current demand is concentrated in private providers serving insured populations, while public-sector adoption is limited by competing health priorities and constrained capital budgets. Expansion beyond major urban centers will require broader screening access and more consistent funding for imaging infrastructure.
GMI Analyst View
We see regional performance being governed by distinct demand mechanisms rather than a single global adoption curve. North America benefits from compliance-led urgency, Europe from organized procurement, Asia Pacific from infrastructure and demographic scale, and Latin America and MEA from selective investment tied to healthcare-system capacity.
Automated Breast Ultrasound Systems Market Share & Competitive Landscape
The global automated breast ultrasound systems (ABUS) market exhibits a moderately concentrated competitive structure, with GE HealthCare, Siemens Healthineers, Philips, Samsung Medison, and Mindray collectively accounting for approximately 74.1% of total market revenue in 2025. Market competition is driven by regulatory approvals, imaging quality, AI-enabled workflow optimization, service capabilities, distribution reach, and long-term relationships with hospitals and diagnostic imaging centers. Established manufacturers benefit from broad installed bases, integrated imaging portfolios, and strong after-sales support networks, creating significant barriers to entry for smaller participants. At the same time, cost-competitive suppliers continue to gain traction in emerging markets where procurement decisions are increasingly influenced by affordability and multi-purpose imaging requirements.
Beyond these leading companies, the market includes several regional manufacturers and specialized imaging technology providers that compete through targeted product offerings, local distribution partnerships, and value-oriented pricing strategies. Overall, the competitive landscape remains characterized by strong technological barriers, increasing integration of artificial intelligence, growing demand for dense-breast screening solutions, and rising emphasis on workflow efficiency. As healthcare providers continue to prioritize early breast cancer detection and high-throughput screening capabilities, competitive success will increasingly depend on imaging performance, clinical validation, interoperability, service excellence, and the ability to support large-scale screening programs.
Recent Industry Developments
GE HealthCare — Invenia ABUS Premium Launch
In March 2025, GE HealthCare introduced Invenia ABUS Premium with Verisound AI for scan-quality assessment, Auto Nipple Detection, and an AI Assistant for lesion detection and characterization [3]GE HealthCare. "GE HealthCare Launches AI-Driven, Patient-Friendly Invenia ABUS Premium to Accelerate Scanning and Drive Early Cancer Detection in Dense Breasts." investor.gehealthcare.com. The launch strengthens the company's dedicated-ABUS differentiation by addressing both acquisition consistency and interpretation workflow, two factors that influence adoption at high-volume screening facilities.
In December 2024, Siemens Healthineers introduced the Acuson Sequoia 3.5 with an HLX high-frequency linear transducer designed for breast imaging [7]Klemovitch R. "RSNA 2024: Siemens Healthineers Introduces Acuson Sequoia 3.5 Ultrasound Update." mpo-mag.com. The update broadened the company's premium-ultrasound proposition and emphasized ergonomics and image-acquisition usability in dense-breast imaging workflows.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →